Sanofi – Sanofi and Regeneron’s Dupixent wins EU approval to deal with kids – PharmaLive
Sanofi and Regeneron’s Dupixent wins EU approval to deal with kids
PARIS (Reuters) – Healthcare corporations Sanofi and Regeneron mentioned on Monday that their Dupixent product has received approval from the European Fee to deal with kids aged 6-11 affected by extreme atopic dermatitis, typically referred to as eczema.
The European Fee had prolonged the advertising and marketing approval for Dupixent within the European Union, each corporations mentioned in a joint assertion, citing a trial that confirmed the product resulted in a mean enchancment of about 80% within the situation of almost three in 4 kids who was affected by extreme atopic dermatitis.
“This approval for Dupixent in the EU represents a major advancement for children with severe atopic dermatitis and their families, who spend countless days and nights tending to their child’s disease with few treatment options to help alleviate the debilitating symptoms,” mentioned George D. Yancopoulos, M.D., Ph.D., president and chief scientific officer at Regeneron.
Reporting by Sudip Kar-Gupta, Modifying by Sherry Jacob-Phillips